Reviewing 4D Molecular Therapeutics (NASDAQ:FDMT) & Siga Technologies (NASDAQ:SIGA)

4D Molecular Therapeutics (NASDAQ:FDMT) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for 4D Molecular Therapeutics and Siga Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1	1	8	0	2.70
Siga Technologies	1	0	0	0	1.00

4D Molecular Therapeutics presently has a consensus target price of $33.25, indicating a potential upside of 255.61%. Given 4D Molecular Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe 4D Molecular Therapeutics is more favorable than Siga Technologies.

Insider & Institutional Ownership

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 2.0% of Siga Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares 4D Molecular Therapeutics and Siga Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$40,000.00	13,354.14	-$160.87 million	($3.75)	-2.49
Siga Technologies	$138.72 million	3.51	$59.21 million	$1.02	6.66

Siga Technologies has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

4D Molecular Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Profitability

This table compares 4D Molecular Therapeutics and Siga Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-174,314.17%	-47.27%	-42.39%
Siga Technologies	43.22%	35.23%	31.06%

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

About Siga Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.